search
Back to results

Examining the Effectiveness of the Nicotine Patch in Male and Female Smokers - 2

Primary Purpose

Tobacco Use Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
nicotine transdermal system
Sponsored by
National Institute on Drug Abuse (NIDA)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tobacco Use Disorder focused on measuring tobacco

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Daily cigarette use of 15 or more cigarettes for at least 2 years Screening CO level of or greater than 15 ppm Normal or corrected-to-normal vision Willing to abstain from tobacco products for 8 or more hours prior to testing Exclusion Criteria: History of chronic health problems or psychiatric conditions History of cardiovascular disease, low or high blood pressure, seizures, head injuries requiring hospital care, peptic ulcer, or diabetes Pregnancy (tested by urinalysis) Scores greater than 17 on the Beck Depression Inventory Lack of a high school degree or GED

Sites / Locations

  • Behavioral Pharmacolgy Research Laboratory

Outcomes

Primary Outcome Measures

Subjective effects
Cognitive performance
Physiologic measures
Smoking Behavior
Plasma Nicotine

Secondary Outcome Measures

Full Information

First Posted
August 23, 2005
Last Updated
January 11, 2017
Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
Virginia Commonwealth University
search

1. Study Identification

Unique Protocol Identification Number
NCT00135746
Brief Title
Examining the Effectiveness of the Nicotine Patch in Male and Female Smokers - 2
Official Title
Effects of Transdermal Nicotine on Tobacco Withdrawal and the Effects of Smoking in Men and Women
Study Type
Interventional

2. Study Status

Record Verification Date
October 2015
Overall Recruitment Status
Completed
Study Start Date
May 2004 (undefined)
Primary Completion Date
May 2007 (Actual)
Study Completion Date
June 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
Virginia Commonwealth University

4. Oversight

5. Study Description

Brief Summary
Treatment studies have demonstrated that current smoking cessation techniques are less effective for women. The purpose of this study is to determine the role that gender plays on the effectiveness of nicotine replacement therapy. This may lead to improved cessation interventions for all smokers, particularly women.
Detailed Description
Currently, about 70 percent of smokers who try to quit by using smoking cessation treatments are unsuccessful. Treatment studies have demonstrated that current smoking cessation techniques are less effective for women. There is no clear explanation for this difference, but it may involve a differential response to nicotine replacement treatments (NRTs) and/or smoking-related stimuli. For women, NRT may be less effective at suppressing withdrawal or blunting the effects of smoking during a quit attempt. Women may also be more sensitive to smoking-related stimuli, such as the taste, sight, and smell of smoke. Tailoring treatment to the separate needs of subgroups, such as men and women, may produce better outcomes. The purpose of this study is to assess the influence of gender on the effectiveness of transdermal nicotine treatment in a group of male and female smokers. Participants in this double-blind, dose-comparison study will complete separate sessions in a random order. Each session will last approximately 6.5 hours and will correspond to a specific transdermal patch dose (0, 7, 14, or 21 mg). Objectively verified cigarette abstinence will be required before each session. Sessions will occur at least 48 hours apart to avoid carryover. Cognitive, behavioral, subjective, and physiological measures will occur during study visits. Specifically, the NRT dose response to tobacco suppression and cigarette blunting effects will be compared in women and men.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco Use Disorder
Keywords
tobacco

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Double
Enrollment
128 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
nicotine transdermal system
Primary Outcome Measure Information:
Title
Subjective effects
Title
Cognitive performance
Title
Physiologic measures
Title
Smoking Behavior
Title
Plasma Nicotine

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Daily cigarette use of 15 or more cigarettes for at least 2 years Screening CO level of or greater than 15 ppm Normal or corrected-to-normal vision Willing to abstain from tobacco products for 8 or more hours prior to testing Exclusion Criteria: History of chronic health problems or psychiatric conditions History of cardiovascular disease, low or high blood pressure, seizures, head injuries requiring hospital care, peptic ulcer, or diabetes Pregnancy (tested by urinalysis) Scores greater than 17 on the Beck Depression Inventory Lack of a high school degree or GED
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Eissenberg, Ph.D.
Organizational Affiliation
Virginia Commonwealth University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Behavioral Pharmacolgy Research Laboratory
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298 0205
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Examining the Effectiveness of the Nicotine Patch in Male and Female Smokers - 2

We'll reach out to this number within 24 hrs